Effect of Polyvinyl Alcohol in Inner Aqueous Phase on Stability of Millimeter-scale Capsules

The millimeter-scale capsules with controllable morphology,ultra-low permeability and excellent mechanical stability were fabricated by millifluidics.Viscosity of inner phase was adjusted to control the morphology and properties of the capsules.In detail,as the concentration of polyvinyl alcohol(PVA)increased from 0 to 8% in the inner phase of the capsules,the diameter of capsules decreased from 3.33 ± 0.01mm to 2.97 ± 0.01 mm,the shell thickness of capsules decreased from 0.183 ± 0.004 mm to 0.155 ± 0.003 mm.While the capsules had round shape and high sphericity.Notably,the capsules with 2% PVA in the inner phase had remarkably decreased water permeability and good morphological stability.Specifically,the end-time of water losing of the capsules was up to 49 days,while the dehydrated capsules maintained spherical appearance,and crushing force of the capsules was up to 13.73 ± 0.79 N,which ensured stability during processing and transportation.This research provides a new strategy for stable encapsulation of small molecules.

Clinical Effect of Yinhuang Qingfei Capsules in Treatment of Asymptomatic and Mild/Common Severe Acute Respiratory Syndrome Coronavirus 2 Infection:An Analysis of 242 Cases

[Objectives]To investigate the clinical effect of Yinhuang Qingfei capsules in the treatment of asymptomatic and mild/common severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection.[Methods]A total of 362 patients with SARS-CoV-2 infection were divided into the treatment group with 242 patients and control group with 120 patients according to their treatment regimen.The patients in the control group were given standard treatment regimen and those in the treatment group were given Yinhuang Qingfei capsules in addition to the treatment in the control group.The two groups were observed in terms of average length of hospital stay,mean time for nucleic acid clearance,TCM syndrome score,and progression to severe/critical illness,and clinical outcome was compared between the two groups.[Results]There was a significant difference in the overall response rate between the treatment group and the control group[97.52%(236/242)vs 95.00%(114/120),P<0.05].Compared with the control group,the treatment group had significantly shorter length of hospital stay and time for nucleic acid clearance(P<0.05).After 7 days of treatment,both groups had a significant change in TCM syndrome score,and there was a significant difference in TCM syndrome score between the two groups(P<0.05);after 15 days of treatment,both groups had a TCM syndrome score of 0.Progression to severe/critical illness was not observed in either group.[Conclusions]Compared with the standard treatment regimen alone,standard treatment regimen combined with Yinhuang Qingfei capsules can effectively shorten the length of hospital stay and time for nucleic acid clearance and improve TCM symptoms in patients with asymptomatic and mild/common SARS-CoV-2 infection.

Study on the Efficacy of Shugan Jieyu Capsules Combined with Trazodone in Patients with Post-Stroke Depression and Insomnia

Objective:To analyze the effectiveness of applying ShuGan JieYu Capsules(SGJYC)combined with trazodone in patients with post-stroke depression(PSD)with insomnia.Methods:60 cases of PSD with insomnia patients admitted to the hospital from May 2022 to May 2023 were selected and randomly divided into a reference group(trazodone)and a research group(SGJYC combined with trazodone)of 30 cases each.Statistics were analyzed using the Hamilton Depression Rating Scale(HAM-D),Pittsburgh Sleep Quality Index(PSQI),and Activities of Daily Living(ADL)scale before treatment and 4,8,and 12 weeks after treatment.Results:Before treatment,The results of HAM-D,PSQI,and ADL scale studies in the two groups before treatment were not statistically significant(P>0.05);4,8,and 12 weeks after treatment,the results of HAM-D and PSQI studies in the research group were lower than that of the reference group,and the results of ADL scale studies were higher than that of the reference group.There was a significant difference between the groups(P<0.05).The total adverse reaction rate of the research group was lower than that of the reference group,and there was a significant difference between the groups(P<0.05).Conclusion:The combination of SGJYC and trazodone reduced depression in post-stroke patients,corrected insomnia,improved sleep quality,was safe,and had a low rate of adverse reactions.

Preparation of multicore millimeter-sized spherical alginate capsules to specifically and sustainedly release fish oil

Specific and sustained release of nutrients from capsules to the gastrointestinal tract has attracted many attentions in the field of food and drug delivery.In this work,we reported a monoaxial dispersion electrospraying-ionotropic gelation technique to prepare multicore millimeter-sized spherical capsules for specific and sustained release of fish oil.The spherical capsules had diameters from 2.05 mm to 0.35 mm with the increased applied voltages.The capsules consisted of uniform(at applied voltages of≤10 k V)or nonuniform(at applied voltages of>10 k V)multicores.The obtained capsules had reasonable loading ratios(9.7%-6.3%)due to the multicore structure.In addition,the obtained capsules had specific and sustained release behaviors of fish oil into the small intestinal phase of in vitro gastrointestinal tract and small intestinal tract models.The simple monoaxial dispersion electrospraying-ionotropic gelatin technique does not involve complicated preparation formulations and polymer modification,which makes the technique has a potential application prospect for the fish oil preparations and the encapsulation of functional active substances in the field of food and drug industries.

Extraction Process and Quality Standard of Danshen Jianxin Capsules

[Objectives]This study was conducted to establish the quality standard of Danshen Jianxin Capsules.[Methods]Orthogonal design was adopted to optimize the water extraction process by taking the amount of water added,extraction time and extraction times as factors,and the content of tanshinone I as the index.Salviae Miltiorrhizae,Notoginseng Radix Et Rhizoma and Radix Astragali in the capsules were qualitatively identified by TLC,and the content of tanshinone I in the capsules was determined by HPLC.[Results]The best water extraction process included the steps of adding 12 times of water each time,extracting the materials twice,for 1 h each time.In TLC identification,the test samples showed spots of the same color at the positions corresponding to tanshinone II A,ginsenoside Rg1,notoginsenoside R1 and astragaloside IV reference samples.[Conclusions]Danshen Jianxin Capsules was prepared by the water extraction method,which is characterized by high efficiency and being suitable for mass production.The quality control method is reliable,fast and accurate,which can effectively control the quality of the product.

Efficacy and safety of Lianhuaqingwen capsules in high-risk common type COVID-19 pneumonia:A multicenter retrospective study

Objective:To evaluate the clinical safety and efficacy of Lianhuaqingwen(LHQW)capsules in patients with high-risk common type COVID-19 pneumonia.Methods:A retrospective multicenter study on 383 high-risk common type COVID-19 pneumonia cases was conducted.Patients were categorized as the standard treatment(SDT)group(n=168)and the LHQW+SDT group(n=215).The primary endpoint was the rate of symptom(fever,fatigue,coughing)recovery and the secondary endpoints included the time to symptom recovery,the proportion of patients with improvement in chest CT images,the proportion of patients with clinical cure,the timing and rate of negative conversion of SARS-CoV-2 RNA assay.Results:The recovery rate was significantly higher in the LHQW+SDT group as compared with the SDT group(89.7%vs.72.0%,P<0.01).The combined use of LHQW+SDT also showed shorter time for symptom recovery,as well as shorter time for individual symptom of fever,fatigue and coughing recovery than use of SDT alone.A higher proportion of patients in the LHQW+SDT group with improvements in chest CT images and clinical cure(77.7%vs.57.1%,P<0.01)but the proportion of patients deteriorating to severe cases(1%vs.25%,P<0.01)in this group was significant lower than those in the SDT group.No significant difference in negative conversion rate of viral assay results was observed(76.8%vs.75.0%,P>0.05).No serious adverse events were reported.Conclusions:LHQW capsules could be recommended to ameliorate clinical symptoms and reduce the rate of deteriorating to severe cases for high-risk common type COVID-19 pneumonia.

Advances in the Intervention of Prunella Spica Capsules on Postoperative Recurrence of Nodular Goiter

As important drugs for the treatment of nodular goiter(NG),Prunella Spica preparations are widely used clinically,and have a significant effect on NG.Various active ingredients in the preparations intervene in the formation of NG by inhibiting the proliferation of thyroid follicular cells,promoting cell apoptosis,regulating immunity,improving the microcirculation of thyroid tissue and other mechanisms,and can reduce the postoperative recurrence of NG.

LipoCol Forte capsules reduce the risk of liver cancer:A propensity score-matched,nationwide,population-based cohort study

BACKGROUND Liver cancer is among the top five most common cancers globally. Lipid-lowering drugs such as statins can lower the risk of liver cancer, but may also cause liver damage. LipoCol Forte capsules(LFC), a red yeast rice product, have demonstrated significant antihypercholesterolemic effects and a good safety profile in clinical studies.AIM To evaluate whether LFC lowers the risk of liver cancer in adults in this propensity score-matched, nationwide, population-based cohort study.METHODS We used data from Taiwan’s National Health Insurance Research Database, which includes electronic medical records for up to 99.99% of Taiwan’s population. LFC users and LFC non-users were matched 1:1 by propensity scores between January 2010 and December 2017. All had followup data for at least 1 year. Statistical analyses compared demographic distributions including sex, age, comorbidities, and prescribed medications. Cox regression analyses estimated adjusted hazard ratios(aHRs) after adjusting for potential confounders.RESULTS We enrolled 33231 LFC users and 33231 non-LFC users(controls). No significant differences between the study cohorts were identified regarding comorbidities and medications [standardized mean difference(SMD) < 0.05]. At follow-up, the overall incidence of liver cancer was significantly lower in the LFC cohort compared with controls [aHR 0.91;95% confidence interval(CI): 0.86-0.95;P < 0.001]. The risk of liver cancer was significantly reduced in both females(aHR 0.87;95%CI: 0.8-0.94;P < 0.001) and males(aHR 0.93;95%CI: 0.87-0.98;P < 0.01) in the LFC cohort compared with their counterparts in the non-LFC cohort. The antitumor protective effects applied to patients with comorbidities(including hypertension, ischemic stroke, diabetes mellitus, hyperlipidemia, hepatitis B infection and hepatitis C infection). Those using LFC for more than 84 drug days had a 0.64-fold lower risk of liver cancer compared with controls(P < 0.001). Compared with controls, the risk of developing liver cancer in the LFC cohort progressively decreased over time;the lowest incidence of liver cancer occurred in LFC users followed-up for more than 6 years(27.44 vs 31.49 per 1,000 person-years;aHR 0.75;95%CI: 0.68-0.82;P < 0.001).CONCLUSION This retrospective cohort study indicates that LFC has a significantly protective effect on lowering the risk of liver cancer, in a dose-dependent and time-dependent manner.

黄莪胶囊对前列腺癌根治术后膀胱功能损伤患者的治疗作用

目的探讨黄莪胶囊对前列腺癌根治术后膀胱功能损伤的临床疗效。方法选取实施腹腔镜下前列腺癌根治术治疗的前列腺癌患者108例,采用随机数字表法将其分为对照组和观察组各54例。对照组术后进行常规抗生素预防感染和康复训练,观察组在对照组基础上给予黄莪胶囊治疗,疗程为42 d。观察两组住院期间的膀胱痉挛和疼痛情况。疗程结束后,采用尿动力学检查仪检测患者最大尿流量、膀胱顺应性、最大逼尿肌压力、最大尿道压,采用国际尿控协会调查问卷评估患者尿控情况、健康调查简表(SF-36)评估治疗前后生活质量、中文版癌症自我管理效能感量表(C-SUPPH)评估自我管理效能。结果与对照组比较,观察组住院期间膀胱痉挛疼痛度降低,痉挛次数、疼痛持续时间减少(P均<0.05)。治疗42 d,观察组最大尿流量、膀胱顺应性、最大逼尿肌压力和最大尿道压力较对照组升高,尿控分级优于对照组,SF-36评分、C-SUPPH各维度评分及总分均高于对照组,差异有统计学意义(P均<0.05)。结论黄莪胶囊对前列腺癌根治术后膀胱功能损伤具有一定治疗作用,可减轻患者术后膀胱痉挛症状,改善尿控和尿动力学指标,提高生活质量。

疏调气机法联合桂枝茯苓胶囊治疗子宫肌瘤的疗效及其对血清TGF-β_(1)、TSGF的影响

目的:探究疏调气机法联合桂枝茯苓胶囊治疗子宫肌瘤的疗效及其对血清转化生长因子β_(1)(transforming growth factor-β_(1),TGF-β_(1))、肿瘤特异性生长因子(tumor specific growth factor,TSGF)的影响。方法:将135例子宫肌瘤患者采用随机数字表法分为对照A组、对照B组和联合组,每组45例。3组均给予常规西药治疗,在此基础上,对照A组采用疏调气机法治疗,对照B组采用桂枝茯苓胶囊治疗,联合组采用疏调气机法联合桂枝茯苓胶囊治疗。比较3组疗效、不良反应发生率及治疗前后子宫肌瘤体积、子宫体积、子宫内膜厚度、中医证候积分、血清雌激素指标[雌二醇(estradiol,E_(2))、黄体生成素(luteinizing hormone,LH)、催乳素(prolactin,PRL)]、氧化应激指标[晚期氧化蛋白产物(advanced oxidation protein products,AOPP)、丙二醛(malonaldehyde,MDA)、超氧化物歧化酶(superoxide dismutase,SOD)]、TGF-β_(1)、TSGF水平。结果:联合组总有效率为97.78%(44/45),高于对照A组的84.44%(38/45)、对照B组的80.00%(36/45)(P<0.05);治疗后3组患者子宫肌瘤体积、子宫体积均小于治疗前,联合组小于对照A组、对照B组;子宫内膜厚度大于治疗前,联合组大于对照A组、对照B组(P<0.05);与本组治疗前比较,治疗后3组患者月经异常、下腹胀痛、面色晦暗积分均降低,联合组低于对照A组、对照B组(P<0.05);治疗后3组患者血清PRL、LH、E_(2)水平均低于治疗前,联合组低于对照A组、对照B组(P<0.05);治疗后3组患者血清SOD水平均高于治疗前,且联合组高于对照A组、对照B组,血清AOPP、MDA水平均低于治疗前,联合组低于对照A组、对照B组(P<0.05);与本组治疗前比较,治疗后3组患者血清TGF-β_(1)、TSGF水平均降低,联合组低于对照A组、对照B组(P<0.05);联合组不良反应发生率为13.33%(6/45),与对照A组的6.67%(3/45)、对照B组的8.89%(4/45)比较,差异无统计学意义(P>0.05)。结论:疏调气机法联合桂枝茯苓胶囊能提高子宫肌瘤临床疗效,下调血清TGF-β_(1)、TSGF水平,且具有一定安全性。

新风胶囊抑制软骨细胞炎症和细胞外基质降解:基于调控miR-502-5p/TRAF2/NF-κB轴

目的探讨新风胶囊(XFC)对白介素(IL)-1β诱导的软骨细胞功能的影响及作用机制。方法构建IL-1β诱导的软骨细胞炎症模型;SD大鼠灌胃制备XFC含药血清。细胞增殖实验(CCK-8)和流式细胞术筛选最佳XFC含药血清浓度;双荧光素酶报告分析miR-502-5p和TRAF2的靶向关系。构建miR-502-5p抑制表达质粒(inhibitor)及阴性对照组,转染至软骨细胞中。分为对照组(NC),IL-1β组,XFC组,IL-1β+NC-inhibitor,IL-1β+miR-502-5pinhibitor,IL-1β+miR-502-5pinhibitor+XFC最佳含药血清组,酶联免疫吸附试验(ELASA)检测IL-1β、肿瘤坏死因子-α(TNF-α)、IL-4、IL-10的水平。逆转录PCR(RT-PCR)、蛋白质免疫印迹实验(WB)、免疫荧光法检测Ⅱ型胶原α1(COL2A1)、基质金属蛋白酶13(MMP13)、软骨蛋白聚糖抗体(ADAMTS5)和miR-502-5p/TRAF2/NF-κB基因的表达。结果与NC组相比,IL-1β组中软骨细胞活力下降,细胞凋亡率升高,且miR-502-5p、IL-4、IL-10和COL2A1表达下降,IL-1β、TNF-α和ADAMTS5、MMP13、TRAF2、NF-κB p65表达升高(P<0.05)。筛选得出20%XFC为最佳含药血清浓度。与IL-1β组相比,XFC含药血清干预后,软骨细胞活力升高,细胞凋亡率下降,IL-1β、TNF-α、ADAMTS5、MMP13、TRAF2、NF-κBp65表达下降,miR-502-5p、IL-4、IL-10和COL2A1表达升高(P<0.05)。与NC-inhibitor相比,转染miR-502-5p inhibitor后,IL-1β、TNF-α、ADAMTS5、MMP13、TRAF2、NF-κB p65表达升高,miR-502-5p、IL-4、IL-10和COL2A1表达下降;与miR-502-5pinhibitor相比,将miR-502-5pinhibitor转染的软骨细胞和最佳XFC含药血清共培养后,XFC含药血清能逆转miR-502-5p抑制状态对软骨细胞炎症和ECM的影响。结论XFC抑制软骨细胞炎症、细胞外基质降解,减轻IL-1β诱导的软骨细胞损伤,其机制可能是通过调节miR-502-5p/TRAF2/NF-κB轴。

基于改进YOLOv5的胶囊内窥镜病灶区域检测

针对目前胶囊内窥镜病灶检测模型存在检测疾病单一且效率低等问题,提出了一种基于YOLOv5的胶囊内窥镜病灶区域检测方法。该方法在原始YOLOv5基础上进行了如下改进:首先,在主干网络Backbone部分,添加一个CBAM(convolutional block attention module)模块,增强模型对重要特征的突出能力;其次,在头部网络Head部分,添加一个检测头,增强模型对小目标的检测能力;最后,将原始YOLOv5的泛化交并比(generalized intersection over union, GIoU)损失函数替换成完整交并比(complete intersection over union, CIoU)损失函数,使模型训练时更快地收敛。本文提出的方法在长江大学第一临床医学院提供的胶囊内窥镜影像数据上进行了实验,精确率达到了93.6%,召回率达到了94.3%,mAP@0.5达到了97.2%,而且检测速度达到了每帧0.027 2 s。实验结果表明提出的方法是有效的、灵活的、鲁棒的,能够满足临床医学诊断的实际需求。

骨疏康胶囊临床综合评价

目的:针对骨疏康胶囊进行综合评价,以期为骨疏康胶囊的临床合理应用提供参考。方法:应用循证医学、流行病学、医学统计学等知识体系,结合相关文献、资料和药品生产企业提供的信息,对骨疏康胶囊的有效性、安全性、经济性、药学特性、质量等方面进行综合评价研究。结果:骨疏康胶囊有效性的Meta分析结果显示,其临床效果优于单一钙剂,可以有效地针对原发性骨质疏松症,且不良反应发生率低;药物吸收快,生物利用度高,服用方便。药品质量符合国家标准且可控,药品说明书及标签、包装符合现行规定。药品价格合理且已被纳入国家医保目录,具有一定的经济性。结论:骨疏康胶囊安全性高,质量可控,临床疗效显著,服用方便,经济性尚可。但部分研究证据级别相对较低,其体内药学特性和可及性方面的研究相对较少,建议进一步深入探讨。

基于空洞分层注意力胶囊网络的X射线焊缝缺陷识别方法

由于X射线焊缝图像的复杂多样性,使得很多传统基于X射线焊缝缺陷检测方法的准确性不高,泛化能力较差。提出一种基于空洞分层注意力胶囊网络(DHACNet)的X射线焊缝缺陷识别方法。DHACNet由卷积模块、空洞分层注意力和胶囊网络(CapsNet)组成。卷积模块用来提取图像的卷积特征,空洞分层注意力用来提取多尺度显著性特征,CapsNet利用胶囊层和动态路由算法替代卷积神经网络(CNN)中的池化操作和全连接操作。DHACNet具有强大多尺度特征提取能力,能够克服CNN只关注图像局部特征和池化操作导致图像部分信息丢失等不足。在构建的X射线焊缝缺陷图像集上进行识别试验,识别准确率为96%以上,与传统方法进行比较,结果表明,该方法有效可行,能够为X射线焊缝缺陷识别系统提供技术支持。

脑栓通胶囊联合丁苯酞胶囊治疗脑梗死恢复期患者的效果观察

目的观察脑栓通胶囊联合丁苯酞胶囊治疗脑梗死恢复期患者的效果。方法104例脑梗死恢复期患者随机分为两组。除基础药物治疗外,对照组给予丁苯酞胶囊治疗,观察组给予脑栓通胶囊联合丁苯酞胶囊治疗。比较两组的脑血流动力学参数、神经功能和日常生活能力。结果治疗后,两组的RI、PI、NIHSS评分均较治疗前降低,且观察组低于对照组(P<0.05);两组的Vm、BI评分均较治疗前提高,且观察组高于对照组(P<0.05)。结论脑栓通胶囊联合丁苯酞胶囊能够明显改善脑梗死恢复期患者的脑血流动力学参数、神经功能和日常生活能力。

航天返回舱雷达探测技术研究

雷达在探测航天返回舱黑障区时,因受到等离子体鞘套干扰,长期存在跟踪不稳定甚至丢失等问题。本文从等离子体鞘套与电磁波相互作用机理出发,提出了航天返回舱黑障区电磁特性仿真方法和再入场景回波仿真方法;结合仿真与实测数据研究获取黑障区目标回波特征,提出了基于鞘套快时变特性的目标检测方法;设计了返回舱黑障区认知探测流程,将其应用于多频段雷达装备成功完成了多次返回舱探测任务,保障了黑障区稳定跟踪,基本解决了航天返回舱黑障区雷达探测问题。

五酯胶囊联合他克莫司在肾移植患者中的疗效及安全性研究

目的 通过分析五酯胶囊联合他克莫司治疗肾移植患者的疗效及安全性,为临床安全合理用药提供依据。方法 回顾性研究2020年1月至2021年2月在中南大学湘雅医院行同种异体肾移植术的患者,分析联用五酯胶囊对他克莫司浓度、肾移植术后常见并发症以及全身免疫炎症指数(SII)的影响,探讨联用五酯胶囊对肾移植患者疗效及安全性的影响。结果 共纳入87例患者,31例(35.63%)患者术后规律使用五酯胶囊,联用达稳态后他克莫司谷浓度较前升高且服药日剂量较前显著下降(P <0.001)。五酯胶囊联用组在术后1个月时血红蛋白为(105.06±15.93)g·L^(-1),显著低于他克莫司单用组(114.58±17.71)g·L^(-1)(P=0.015),在术后3个月时逐渐升高且两组间差异消失。五酯胶囊联用组全身免疫炎症指数在术后1个月无明显变化,术后3个月显著下降(P=0.006)。结论 五酯胶囊联合他克莫司可显著提高肾移植患者他克莫司的血药浓度且减少用药剂量,联合用药初期应关注患者贫血情况。五酯胶囊对肾移植患者全身免疫炎症状态的影响仍需进一步研究。

HPLC法测定肾康灵胶囊中盐酸小檗碱的含量

目的 建立肾康灵胶囊中盐酸小檗碱的HPLC含量测定方法,为质量控制提供依据。方法 采用HPLC法,色谱柱:Sapphire-C_(18)柱(4.6×250 mm, 5μm);流动相:乙腈-0.1%磷酸溶液(梯度洗脱);流动相流速:1.0 mL·min^(-1);检测波长:265 nm;柱温:30℃,进样量:10μL。结果 盐酸小檗碱含量在0.0584~0.5840μg范围内与峰面积值呈良好线性关系(R^(2)=0.9981),精密度和重复性试验的RSD均<2.0%(n=6),稳定性试验(18 h内)的RSD为1.11%,平均加样回收率为98.24%,RSD=1.43%(n=6)。结论 该方法快速简便、稳定性好,专属性强,重复性良好,可为肾康灵胶囊的质量控制提供依据。

JCapsR:一种联合胶囊神经网络的藏语知识图谱表示学习模型

知识图谱表示学习是自然语言处理的一项关键技术,现有的知识图谱表示研究主要集中在英语、汉语等语言,而低资源语言的知识图谱表示学习研究还处于探索阶段,如藏语。该文基于前期构建的藏语知识图谱,提出了一种联合胶囊神经网络(JCapsR)的藏语知识图谱表示学习模型。首先,我们使用TransR模型生成藏语知识图谱的结构化信息表示。其次,采用融合多头注意力和关系注意力的Transfomer模型表示藏语实体的文本描述信息。最后,采用JCapsR进一步提取三元组在知识图谱语义空间中的关系,将实体文本描述信息和结构化信息融合,得到藏语知识图谱的表示,相比基线系统,联合胶囊神经网络JCapsR模型提高了在藏语知识图谱上实体链接预测的性能,相关研究为其他低资源语言知识图谱表示学习的拓展优化提供了参考借鉴意义。

藤黄健骨胶囊对PMOP大鼠RANKL/c-Fos/NFATc1通路的影响

目的探讨免疫调节分子IL-33对绝经后骨质疏松症(postmenopausal osteoporosis,PMOP)模型鼠RANKL/c-Fos/NFATc1信号轴的调控作用及藤黄健骨胶囊(Tenghuang Jiangu capsule,TJC)的干预机制。方法构建PMOP大鼠模型,设置假手术组、PMOP模型组、阳性对照组(0.09 mg/kg)和TJC高、中、低剂量组(0.36、0.18、0.09 g/kg),灌胃给药,每天1次,持续8周。从大鼠末次给药后体质量、骨密度(bone mineral density,BMD)及股骨组织微结构等方面评价TJC的疗效;通过ELISA分析TJC对大鼠血清免疫调节因子IL-33、IL-1、IL-31变化;运用qPCR和Western blotting分析TJC对大鼠股骨OPG、RANKL、RANK、c-Fos、NFATc1表达量的影响。结果与假手术组相比,PMOP模型组大鼠的体质量、骨髓脂肪组织相对面积(relative area of bone marrow adipose tissue,BMAT),IL-1、IL-31变化,RANKL、RANK、c-Fos、NFATc1的表达均出现了明显升高的趋势,而BMD、IL-33变化、OPG的表达则出现了明显下降的趋势(P<0.01);与PMOP模型组相比,TJC高剂量组大鼠体质量出现显著下降趋势、IL-33变化出现显著升高趋势(P<0.01),TJC中、高剂量组大鼠BMAT、RANK的表达出现显著下降趋势、OPG的表达出现显著升高趋势(P<0.05或P<0.01),TJC各剂量组大鼠IL-1、IL-31变化,RANKL、c-Fos、NFATc1出现显著降低趋势,BMD出现显著增加趋势(P<0.05或P<0.01)。结论TJC能够提高PMOP大鼠免疫调控分子IL-33含量,抑制免疫调控分子IL-1、IL-31含量和破骨细胞分化标志分子NFATc1的表达,其机制可能与RANKL/c-Fos/NFATc1抑制骨代谢通路密切相关。